HC Wainwright & Co. Reiterates Buy Rating on Halozyme Therapeutics, Inc. (HALO)

Market Context

Halozyme Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $78.33 with a market capitalization of $7.3B. The stock has gained 33.4% over the past 52 weeks.

Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Halozyme Therapeutics, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Halozyme Therapeutics, Inc.

Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 21, 2026	HC Wainwright & Co.	Buy	N/A
May 12, 2026	Morgan Stanley	Overweight	N/A
Apr 29, 2026	HC Wainwright & Co.	Buy	N/A
Feb 19, 2026	Benchmark	Buy	N/A
Feb 19, 2026	Wells Fargo	Equal-Weight	N/A

Related Tools: Analyst Ratings Dashboard | View HALO Stock Page